ciclesonide (alvesco) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ciclesonide is a glucocorticoid receptor agonist indicated for the treatment of allergic rhinitis (Omnaris nasal spray) and asthma (Alvesco). It was also developed by Byk Gulden for chronic obstructive pulmonary disease (COPD), but no development had been reported for this indication since 1999. Ciclesonide is a pro-drug and rapidly metabolized to C21-desisobutyryl-ciclesonide which is more potent toward GR receptor than the parent drug.   NCATS

Chemistry

  • SMILES: CC(C)C(=O)OCC(=O)[C@@]12O[C@@H](O[C@@H]1C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]23C)C6CCCCC6
  • InChIKey: LUKZNWIVRBCLON-GXOBDPJESA-N
  • Mol. Mass: 540.6876
  • ALogP: 4.7
  • ChEMBL Molecule:
    ciclesonide  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Topical
  • Pro Drug: Yes

Drug Pricing (per unit)

United States

$3.0400 - $23.3100

Australia

$11.3737 - $20.7625
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

alvesco | alvesco 160 | alvesco 80 | ave2635a | ciclesonide | omnaris | (r)-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate | rpr-251526 | zetonna

Organizations (55)

Research & Development (53)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (13)

Approved Indications (3)


 

Asthma

Rhinitis, Allergic, Perennial (approved 2006)

Rhinitis, Allergic, Seasonal

Experimental Indications - Clinical Trial Phases 1-4 (13)


 

Asthma ()

Coronavirus Infections (Phase 2)

COVID-19 (Phase 3)

Healthy Volunteers (Phase 1)

Nasal Polyps (Phase 3)

Pneumonia, Viral (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Respiratory Hypersensitivity (Phase 3)

Respiratory Tract Diseases (Phase 3)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Perennial (Phase 4)

Rhinitis, Allergic, Seasonal ()

SARS-CoV-2 (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 76
  • # of Trial Organizations: 53

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue